Pacira BioSciences, Inc. - Common Stock, par value $0.001 per share (PCRX)

Historical Holders from Q1 2014 to Q3 2025

Symbol
PCRX on Nasdaq
CUSIP
695127100
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
44.9M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
50.5M
Holdings value
$1.21B
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
230
Number of buys
113
Number of sells
-108
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Pacira BioSciences, Inc. - Common Stock, par value $0.001 per share (PCRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15.2% $184M 7.02M BlackRock, Inc. Mar 31, 2025
Doma Perpetual Capital Management LLC 5.7% $67.8M 2.7M Doma Perpetual Capital Management LLC Aug 1, 2025
RENAISSANCE TECHNOLOGIES LLC 5.34% $62.6M 2.4M Renaissance Technologies LLC Apr 8, 2025
Pacer Advisors, Inc. 1.28% -80.7% $15.8M -$69.9M 602K -81.6% Pacer Advisors, Inc. Mar 31, 2025
MILLENNIUM MANAGEMENT LLC 0.7% -88% $9.08M -$52.3M 346K -85.2% Millennium Management LLC Mar 31, 2025

Institutional Holders of Pacira BioSciences, Inc. - Common Stock, par value $0.001 per share (PCRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 955K $24.6M -$11.1M $25.77 21
2025 Q2 50.5M $1.21B +$1.09M $23.90 230
2025 Q1 50.6M $1.26B +$32.6M $24.85 233
2024 Q4 49.9M $941M -$11.9M $18.84 228
2024 Q3 51M $768M -$173M $15.05 237
2024 Q2 51.9M $1.49B +$81.6M $28.61 276
2024 Q1 48.9M $1.43B +$11.7M $29.22 266
2023 Q4 83K $2.8M -$402K $33.74 3
2023 Q3 47M $1.44B -$4.93M $30.68 250
2023 Q2 46.6M $1.87B +$9.97M $40.07 248
2023 Q1 46.3M $1.89B -$75M $40.81 262
2022 Q4 48.3M $1.86B -$48.6M $38.61 264
2022 Q3 46.7M $2.48B +$82.3M $53.19 250
2022 Q2 48.8M $2.85B -$35.7M $58.30 267
2022 Q1 49.5M $3.77B -$68M $76.32 284
2021 Q4 50.5M $3.04B +$80.6M $60.17 261
2021 Q3 49.1M $2.75B -$7.82M $56.00 250
2021 Q2 49.2M $2.98B -$36.5M $60.68 253
2021 Q1 49.8M $3.49B -$29M $70.09 266
2020 Q4 50.3M $3.01B +$131M $59.84 255
2020 Q3 48.2M $2.9B -$13.4M $60.12 253
2020 Q2 48.7M $2.56B +$107M $52.47 240
2020 Q1 47M $1.57B +$37.7M $33.53 212
2019 Q4 45.3M $2.05B +$15.6M $45.30 224
2019 Q3 45.1M $1.72B +$75.6M $38.07 204
2019 Q2 42.8M $1.86B +$131M $43.49 215
2019 Q1 41.3M $1.57B +$30M $38.06 202
2018 Q4 39.8M $1.71B -$35.2M $43.02 198
2018 Q3 40.4M $1.98B -$82.9M $49.15 178
2018 Q2 42.4M $1.36B -$4.23M $32.05 145
2018 Q1 43.6M $1.36B +$18.5M $31.15 161
2017 Q4 41.6M $1.9B -$63.9M $45.65 179
2017 Q3 43.5M $1.64B +$59.8M $37.55 175
2017 Q2 41M $1.96B +$8.54M $47.70 189
2017 Q1 40.9M $1.87B +$210M $45.60 187
2016 Q4 39.9M $1.29B +$17.8M $32.30 177
2016 Q3 39.4M $1.35B -$48.8M $34.22 175
2016 Q2 40.7M $1.37B -$219M $33.73 180
2016 Q1 42.9M $2.27B -$34M $52.98 173
2015 Q4 42.1M $3.23B +$16.6M $76.79 209
2015 Q3 41.7M $1.71B -$38.7M $41.10 174
2015 Q2 42.4M $3B +$147M $70.72 185
2015 Q1 40.3M $3.58B +$97.5M $88.85 204
2014 Q4 37.9M $3.36B -$15.2M $88.66 196
2014 Q3 38.6M $3.74B +$110M $96.92 204
2014 Q2 37.6M $3.45B +$245M $91.86 188
2014 Q1 35.1M $2.45B +$23.2M $69.99 158